Efficiency of a combination of vaccines against the virus Ebola] is estimate

Two clinical trials showed efficiency of the scheme of reception of a combination of vaccines from the virus Ebola. Results both the first, and the second tests are published in The Lancet by Infectious Diseases. During two researches to Sierra Leone — among children from one to 17 years and among adults 18 years are more senior — the consortium EBOVAC1 estimated joint action of two preparations: vaccines of Ad26.ZEBOV from Johnson & Johnson Inc. and the developed Danish company Bavarian Nordic MVA-BN-Filo. During the first phase of 43 adults received the second vaccine in 56 days after the first. In the second — 400...